Short Interest in Moleculin Biotech, Inc. (NASDAQ:MBRX) Increases By 17.0%

Moleculin Biotech, Inc. (NASDAQ:MBRX) was the target of a significant growth in short interest during the month of September. As of September 15th, there was short interest totalling 125,200 shares, a growth of 17.0% from the August 31st total of 107,000 shares. Based on an average daily trading volume, of 37,100 shares, the short-interest ratio is currently 3.4 days. Approximately 4.6% of the company’s shares are sold short.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on Moleculin Biotech in a research report on Thursday. They issued a “sell” rating for the company.

Moleculin Biotech Price Performance

Shares of Moleculin Biotech stock traded down $0.08 on Monday, reaching $2.67. 12,495 shares of the company’s stock were exchanged, compared to its average volume of 31,336. Moleculin Biotech has a 52 week low of $2.12 and a 52 week high of $15.75. The firm’s 50-day moving average is $2.60 and its two-hundred day moving average is $3.98.

Moleculin Biotech (NASDAQ:MBRX) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($2.23) EPS for the quarter, missing analysts’ consensus estimates of ($2.10) by ($0.13). On average, equities analysts predict that Moleculin Biotech will post -8.6 earnings per share for the current year.

Hedge Funds Weigh In On Moleculin Biotech

A hedge fund recently raised its stake in Moleculin Biotech stock. Armistice Capital LLC increased its position in Moleculin Biotech, Inc. (NASDAQ:MBRX) by 5.1% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 156,000 shares of the company’s stock after purchasing an additional 7,505 shares during the period. Armistice Capital LLC owned approximately 6.75% of Moleculin Biotech worth $549,000 at the end of the most recent quarter. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.